Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 3, 2015, Pages 222-226

  Durante Mangoni, Emanuele ^a   Del Franco, Mariateresa ^b   Andini, Roberto ^a   Bernardo, Mariano ^a   Giannouli, Maria ^b   Zarrilli, Raffaele ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acinetobacter baumannii; Colistin resistance; Colistin therapy; In vitro fitness; In vivo virulence; PmrB mutation

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; IMIPENEM; IMMUNOGLOBULIN; MEROPENEM; METHYLPREDNISOLONE; METICILLIN; MYCOPHENOLATE MOFETIL; PHOSPHOTRANSFERASE; PMRB SENSOR KINASE; POLYCLONAL ANTIBODY; THYMOCYTE ANTIBODY; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; PMRB PROTEIN, BACTERIA; TRANSCRIPTION FACTOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; DRUG MEGADOSE; ENTEROCOCCAL INFECTION; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII; FEMALE; GENOTYPE; HUMAN; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; LUNG INFILTRATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; CASE REPORT; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOCOMPROMIZED PATIENT; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; VERY ELDERLY; VIRULENCE; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MUTATION; TRANSCRIPTION FACTORS; VIRULENCE; YOUNG ADULT;

EID: 84941876980     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.03.013     Document Type: Article

References (21)

1. Adams M.D., Nickel G.C., Bajaksouzian S., Lavender H., Murthy A.R., Jacobs M.R., et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009, 53(9):3628-3634.
2. Beceiro A., Llobet E., Aranda J., Bengoechea J.A., Doumith M., Hornsey M., et al. Phosphoethanolamine modification of lipidA in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011, 55(7):3370-3379.
3. Beceiro A., Moreno A., Fernández N., Vallejo J.A., Aranda J., Adler B., et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 2014, 58(1):518-526.
4. Bonnet R., Charon F., Cavallo J.D., Chardon H., Chidiac C., Courvalin P., et al. Comitè de l'antibiogramme de la Societe Francaise de Microbiologie. Recommandations 2013, (Available at: http://www.sfm-microbiologie.org/. Accessed 18 November 2014).
5. Cannatelli A., Di Pilato V., Giani T., Arena F., Ambretti S., Gaibani P., et al. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment. Antimicrob Agents Chemother 2014, 58(8):4399-4403.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing, 20th informational supplement. M100-S20 2010, CLSI, Wayne, PA.
7. Durante-Mangoni E., Signoriello G., Andini R., Mattei A., De Cristoforo M., Murino P., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013, 57(3):349-358.
8. Durante-Mangoni E., Utili R., Zarrilli R. Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date. Future Microbiol 2014, 9(6):773-789.
9. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee EUCAST technical note on tigecycline. Clin Microbiol Infect 2006, 12(11):1147-1149.
10. Giannouli M., Cuccurullo S., Crivaro V., Di Popolo A., Bernardo M., Tomasone F., et al. Molecular epidemiology of multi-drug resistant Acinetobacter baumannii in a tertiary care hospital in Naples, Italy, shows the emergence of a novel epidemic clone. J Clin Microbiol 2010, 48(4):1223-1230.
11. Giannouli M., Antunes L.C.S., Marchetti V., Triassi M., Visca P., Zarrilli R. Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78. BMC Infect Dis 2013, 13:282.
12. Janssen P., Maquelin K., Coopman R., Tjernberg I., Bouvet P., Kersters K., et al. Discrimination of Acinetobacter genomic species by AFLP fingerprinting. Int J Syst Bacteriol 1997, 47(4):1179-1187.
13. Lesho E., Yoon E.J., McGann P., Snesrud E., Kwak Y., Milillo M., et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis 2013, 208(7):1142-1151.
14. Lopez-Rojas R., Dominguez-Herrera J., McConnell M.J., Docobo-Perez F., Smani Y., Fernandez-Reyes M., et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011, 203(4):545-548.
15. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281.
16. Moffatt J.H., Harper M., Harrison P., Hale J.D., Vinogradov E., Seemann T., et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010, 54(12):4971-4977.
17. Pournaras S., Poulou A., Dafopoulou K., Chabane Y.N., Kristo I., Makris D., et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii. Antimicrob Agents Chemother 2014, 58(2):828-832.
18. Snitkin E.S., Zelazny A.M., Gupta J., NISC Comparative Sequencing Program, Palmore T.N., Murray P.R., et al. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res 2013, 23(7):1155-1162.
19. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33(9):2233-2239.
20. Zarrilli R., Giannouli M., Rocco F., Loman N.J., Haynes A.S., Constantinidou C., et al. Genome sequences of three Acinetobacter baumannii strains assigned to ST2, ST25 and ST78 multilocus sequencing typing genotypes. J Bacteriol 2011, 193(9):2359-2360.
21. Zarrilli R., Pournaras S., Giannouli M., Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 2013, 41(1):11-19.